Trial Profile
Phase II Study of Single Agent Sorafenib in the Treatment of Relapsed Esophageal/Gastric Adenocarcinoma in Platinum Pre-Treated Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 22 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 18 Jan 2014 Interim results presented at the 2014 Gastrointestinal Cancers Symposium.
- 09 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.